NEXT-GENERATION NANOTECHNOLOGY.KNOW-HOW, TODAY.

OUR SMART STORY


Creating formulations that are truly effective means finding an answer to the question of solubility – and that answer can be found in LEON’s unique approach to nano. For both New Chemical Entities (NCEs) and generics, our intelligence in nanotechnology provides a clear solution to poor solubility and paves the way for downstream processing. With this we address unmet patient needs and unlock new value from APIs for pharmaceutical partners.

Our solution is based on patented technologies to deliver a classic bottom-up approach to the synthesis of SMART nanoparticles or microparticles. This results in the continuous precipitation of particle sizes between 10 nm and to 70 µm with consistent reproducibility and at a cost comparative to standard technologies for small and large scales.

SMART nano-particleTM

Our definition of SMART

Stable crystalline or polymeric particles
Measurable tailored size: 10 nm – 70 µm
Achievable easy scale-up: bench to commercial
Relevant for all application forms
Timebound: fast continuous precipitation < 0.1 ms easily integrated into downstream processes

Our development pathway and equipment allows easy scale-up to test prototype nano formulations as well as to support clinical and commercial availability. New formulations can be developed faster and the process can be validated easily. Thus, positive impacts for patients can be achieved faster.

Standardized, continuous processing

Easily scalable

Proprietary Technology

Particle tolerances between 10 nm – 1000 nm and 1-70 µm

Suitable for range of drug delivery dosage forms

OUR TECHNOLOGY


High-precision particle synthesis.

At LEON, we employ proprietary nano technology (including (MJR®)) to provide a highly controlled environment for the repeatable production of stable nanoparticles between 10 nm and 1000 nm and for micro 1-70 µm in size.

Because we take a bottom-up approach to particle synthesis, we avoid the known difficulties associated with top-down nano methods, such as wet-milling, where the presence of heat and the impact of shearing, together with the inherently high investment cost and the high failure rate, make it an unsuitable option for many candidate molecules and their organizations.

LEON can quickly and reliably produce a wide range of nano particles by customizing process conditions to the API. These include surface-stabilized nanocrystals, micelles, liposomes, nanoemulsions, polymeric nanoparticles and even solid lipid nanoparticles. Our proprietary approach shares the same fundamental process for small-scale testing as it does for full-scale production, providing a swift and cost-effective route to commercial development.

How it works

A solvent and non-solvent collide inside the reactor’s chamber.

This results in the precipitation of insoluble compounds.

Nanoparticles suspended in the liquid are ready for downstream processing.

LEON offers a broad range of particle types to meet a variety of requirements, whenever there is a need to re-produce easily and with scale, including:

SURFACE-STABILISED CRYTALLINE NANOPARTICLES

POLYMERIC NANOPARTICLES

LIPOSOMES

SOLID-LIPID NANOPARTICLES

NANOEMULSIONS

MICELLES

OUR SERVICE


At LEON, we provide all the services needed to support Drug Product formulation delivery at nano scale, from initial concept through to product approval.

We work collaboratively with our pharmaceutical partners on a contract or co-development basis. The engagement process typically follows key stages.

nanoSOLV